Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells

Blood

Volumn 115, Issue 14, 2010, Pages 2960-2970

  Moosmann, Andreas ^a,b   Bigalke, Iris ^b   Tischer, Johanna ^a   Schirrmann, Leah ^a   Kasten, Julitta ^b   Tippmer, Stefanie ^b   Leeping, Marina ^a   Prevalšek, Dušan ^a   Jaeger, Gundula ^a   Ledderose, Georg ^a   Mautner, Josef ^c   Hammerschmidt, Wolfgang ^b   Schendel, Dolores J ^b   Kolb, Hans Jochem ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CIDOFOVIR; CYCLOSPORIN A; GAMMA INTERFERON; METHOTREXATE; RITUXIMAB;

ADOPTIVE TRANSFER; ADULT; AMINO ACID SEQUENCE; ARTICLE; BLOOD DONOR; CD8+ T LYMPHOCYTE; CELL ISOLATION; CELL STIMULATION; CELL TRANSPLANTATION; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSPOT ASSAY; EPSTEIN BARR VIRUS; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOMAGNETIC SEPARATION; LYMPHOPROLIFERATIVE DISEASE; MALE; MULTIPLE ORGAN FAILURE; PERIPHERAL LYMPHOCYTE; POLYMERASE CHAIN REACTION; POSTTRANSPLANTATION LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; PROPHYLAXIS; REMISSION; TREATMENT RESPONSE;

EID: 77951058615     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-08-236356     Document Type: Article

References (59)

1. Hislop AD, Taylor GS, Sauce D, Rickinson AB. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol. 2007;25:587-617. (Pubitemid 46697918)
2. Gottschalk S, Rooney CM, Heslop HE. Post-transplant lymphoproliferative disorders. Annu Rev Med. 2005;56:29-44.
3. Landgren O, Gilbert ES, Rizzo JD, et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood. 2009;113(20):4992-5001.
4. Meij P, van Esser JW, Niesters HG, et al. Impaired recovery of Epstein-Barr virus (EBV)-specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease. Blood. 2003;101(11):4290-4297. (Pubitemid 36857791)
5. Meijer E, Cornelissen JJ. Epstein-Barr virus-associated lymphoproliferative disease after allogeneic haematopoietic stem cell transplantation: molecular monitoring and early treatment of high-risk patients. Curr Opin Hematol. 2008;15(6):576-585.
6. Kuehnle I, Huls MH, Liu Z, et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood. 2000;95(4):1502-1505. (Pubitemid 30099868)
7. O'Reilly RJ, Small TN, Papadopoulos E, Lucas K, Lacerda J, Koulova L. Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts. Immunol Rev. 1997;157:195-216. (Pubitemid 27303130)
8. Heslop HE, Ng CY, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med. 1996;2(5):551-555. (Pubitemid 26150682)
9. Rooney CM, Smith CA, Ng CY, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet. 1995;345(8941):9-13.
10. Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998;92(5): 1549-1555.
11. Fujita Y, Rooney CM, Heslop HE. Adoptive cellular immunotherapy for viral diseases. Bone Marrow Transplant. 2008;41(2):193-198. (Pubitemid 351188917)
12. Bollard CM, Cooper LJ, Heslop HE. Immunotherapy targeting EBV-expressing lymphoproliferative diseases. Best Pract Res Clin Haematol. 2008;21(3):405-420.
13. Becker C, Pohla H, Frankenberger B, et al. Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay. Nat Med. 2001;7(10):1159-1162. (Pubitemid 33010027)
14. Rauser G, Einsele H, Sinzger C, et al. Rapid generation of combined CMV-specific CD4+ and CD8+ T-cell lines for adoptive transfer into recipients of allogeneic stem cell transplants. Blood. 2004;103(9):3565-3572. (Pubitemid 38525695)
15. Lee SP, Thomas WA, Murray RJ, et al. HLAA2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2. J Virol. 1993;67(12):7428-7435.
16. Scotet E, David-Ameline J, Peyrat MA, et al. T cell response to Epstein-Barr virus transactivators in chronic rheumatoid arthritis. J Exp Med. 1996;184(5):1791-1800. (Pubitemid 26404470)
17. Steven NM, Annels NE, Kumar A, Leese AM, Kurilla MG, Rickinson AB. Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response. J Exp Med. 1997;185(9):1605-1617. (Pubitemid 27203257)
18. Saulquin X, Ibisch C, Peyrat MA, et al. A global appraisal of immunodominant CD8 T cell responses to Epstein-Barr virus and cytomegalovirus by bulk screening. Eur J Immunol. 2000; 30(9):2531-2539.
19. Hill AB, Lee SP, Haurum JS, et al. Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised. J Exp Med. 1995; 181(6):2221-2228.
20. Hill A, Worth A, Elliott T, et al. Characterization of two Epstein-Barr virus epitopes restricted by HLA-B7. Eur J Immunol. 1995;25(1):18-24.
21. Burrows SR, Gardner J, Khanna R, et al. Five new cytotoxic T cell epitopes identified within Epstein-Barr virus nuclear antigen 3. J Gen Virol. 1994;75(Pt 9):2489-2493. (Pubitemid 24282270)
22. Bogedain C, Wolf H, Modrow S, Stuber G, Jilg W. Specific cytotoxic T lymphocytes recognize the immediate-early transactivator Zta of Epstein-Barr virus. J Virol. 1995;69(8):4872-4879.
23. Gavioli R, Kurilla MG, de Campos-Lima PO, et al. Multiple HLAA11-restricted cytotoxic T-lymphocyte epitopes of different immunogenicities in the Epstein-Barr virus-encoded nuclear antigen 4. J Virol. 1993;67(3):1572-1578. (Pubitemid 23067665)
24. Rickinson AB, Moss DJ. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol. 1997;15:405-431. (Pubitemid 27169287)
25. Kuzushima K, Hayashi N, Kudoh A, et al. Tetramer-assisted identification and characterization of epitopes recognized by HLAA*2402-restricted Epstein-Barr virus-specific CD8+ T cells. Blood. 2003;101(4):1460-1468. (Pubitemid 36182521)
26. Brooks JM, Murray RJ, Thomas WA, Kurilla MG, Rickinson AB. Different HLA-B27 subtypes present the same immunodominant Epstein-Barr virus peptide. J Exp Med. 1993;178(3):879-887.
27. Lee SP, Thomas WA, Blake NW, Rickinson AB. Transporter (TAP)-independent processing of a multiple membrane-spanning protein, the Epstein-Barr virus latent membrane protein 2. Eur J Immunol. 1996;26(8):1875-1883.
28. Khanna R, Burrows SR, Kurilla MG, et al. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development. J Exp Med. 1992; 176(1):169-176.
29. Landais E, Saulquin X, Scotet E, et al. Direct killing of Epstein-Barr virus (EBV)-infected B cells by CD4 T cells directed against the EBV lytic protein BHRF1. Blood. 2004;103(4):1408-1416. (Pubitemid 38168656)
30. Adhikary D, Behrends U, Moosmann A, Witter K, Bornkamm GW, Mautner J. Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins. J Exp Med. 2006; 203(4):995-1006.
31. Mautner J, Pich D, Nimmerjahn F, et al. Epstein-Barr virus nuclear antigen 1 evades direct immune recognition by CD4+ T helper cells. Eur J Immunol. 2004;34(9):2500-2509. (Pubitemid 39302807)
32. Leen A, Meij P, Redchenko I, et al. Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses. J Virol. 2001;75(18):8649-8659. (Pubitemid 32768969)
33. Milosevic S, Behrends U, Adhikary D, Mautner J. Identification of major histocompatibility complex class II-restricted antigens and epitopes of the Epstein-Barr virus by a novel bacterial expression cloning approach. J Virol. 2006;80(21):10357-10364. (Pubitemid 44628883)
34. Campe H, Jaeger G, Abou-Ajram C, et al. Serial detection of Epstein-Barr virus DNA in sera and peripheral blood leukocyte samples of pediatric renal allograft recipients with persistent mononucleosis-like symptoms defines patients at risk to develop post-transplant lymphoproliferative disease. Pediatr Transplant. 2003;7(1):46-52. (Pubitemid 36314190)
35. Brennan RM, Burrows SR. A mechanism for the HLA-A*01-associated risk for EBV+ Hodgkin lymphoma and infectious mononucleosis. Blood. 2008;112(6):2589-2590.
36. Adhikary D, Behrends U, Boerschmann H, et al. Immunodominance of lytic cycle antigens in Epstein-Barr virus-specific CD4+ T cell preparations for therapy. PLoS ONE. 2007;2(7):e583. (Pubitemid 351266394)
37. Champagne P, Ogg GS, King AS, et al. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature. 2001;410(6824):106-111. (Pubitemid 32225845)
38. Hislop AD, Annels NE, Gudgeon NH, Leese AM, Rickinson AB. Epitope-specific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein-Barr virus infection. J Exp Med. 2002;195(7):893-905.
39. Hislop AD, Gudgeon NH, Callan MF, et al. EBV-specific CD8+ T cell memory: relationships between epitope specificity, cell phenotype, and immediate effector function. J Immunol. 2001; 167(4):2019-2029.
40. Dunne PJ, Belaramani L, Fletcher JM, et al. Quiescence and functional reprogramming of Epstein-Barr virus (EBV)-specific CD8+ T cells during persistent infection. Blood. 2005;106(2): 558-565. (Pubitemid 40981251)
41. Styczynski J, Einsele H, Gil L, Ljungman P. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Transpl Infect Dis. 2009;11(5):383-392.
42. Faye A, Quartier P, Reguerre Y, et al. Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children. Br J Haematol. 2001;115(1):112-118. (Pubitemid 32995103)
43. Comoli P, Basso S, Zecca M, et al. Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation. Am J Transplant. 2007;7(6):1648-1655. (Pubitemid 46776261)
44. Gustafsson A, Levitsky V, Zou JZ, et al. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood. 2000;95(3): 807-814. (Pubitemid 30062700)
45. Haque T, Wilkie GM, Jones MM, et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood. 2007;110(4):1123-1131. (Pubitemid 47281407)
46. Cobbold M, Khan N, Pourgheysari B, et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med. 2005;202(3): 379-386. (Pubitemid 41126955)
47. Hammer MH, Meyer S, Brestrich G, et al. HLA type-independent generation of antigen-specific T cells for adoptive immunotherapy. Eur J Immunol. 2005;35(7):2250-2258. (Pubitemid 41015064)
48. Feuchtinger T, Lang P, Hamprecht K, et al. Isolation and expansion of human adenovirus-specific CD4+ and CD8+ T cells according to IFN-gamma secretion for adjuvant immunotherapy. Exp Hematol. 2004;32(3):282-289. (Pubitemid 38328534)
49. Feuchtinger T, Richard C, Joachim S, et al. Clinical grade generation of hexon-specific T cells for adoptive T-cell transfer as a treatment of adenovirus infection after allogeneic stem cell transplantation. J Immunother. 2008;31(2):199-206.
50. Feuchtinger T, Matthes-Martin S, Richard C, et al. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol. 2006;134(1):64-76. (Pubitemid 43830030)
51. Hammer MH, Brestrich G, Mittenzweig A, et al. Generation of EBV-specific T cells for adoptive immunotherapy: a novel protocol using formalin-fixed stimulator cells to increase biosafety. J Immunother (1997). 2007;30(8):817-824. (Pubitemid 350295360)
52. Fujita Y, Leen AM, Sun J, et al. Exploiting cytokine secretion to rapidly produce multivirusspecific T cells for adoptive immunotherapy. J Immunother. 2008;31(7):665-674.
53. Wehler TC, Karg M, Distler E, et al. Rapid identification and sorting of viable virus-reactive CD4(+) and CD8(+) T cells based on antigen-triggered CD137 expression. J Immunol Methods. 2008; 339(1):23-37.
54. Hislop AD, Kuo M, Drake-Lee AB, et al. Tonsillar homing of Epstein-Barr virus-specific CD8+ T cells and the virus-host balance. J Clin Invest. 2005;115(9):2546-2555.
55. Montone KT, Hodinka RL, Salhany KE, Lavi E, Rostami A, Tomaszewski JE. Identification of Epstein-Barr virus lytic activity in post-transplantation lymphoproliferative disease. Mod Pathol. 1996;9(6):621-630.
56. Hong GK, Gulley ML, Feng WH, Delecluse HJ, Holley-Guthrie E, Kenney SC. Epstein-Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model. J Virol. 2005; 79(22):13993-14003. (Pubitemid 41552698)
57. Hong GK, Kumar P, Wang L, et al. Epstein-Barr virus lytic infection is required for efficient production of the angiogenesis factor vascular endothelial growth factor in lymphoblastoid cell lines. J Virol. 2005;79(22):13984-13992. (Pubitemid 41552697)
58. Burrows SR, Khanna R, Burrows JM, Moss DJ. An alloresponse in humans is dominated by cytotoxic T lymphocytes (CTL) cross-reactive with a single Epstein-Barr virus CTL epitope: implications for graft-versus-host disease. J Exp Med. 1994;179(4):1155-1161. (Pubitemid 24091774)
59. Leen AM, Myers GD, Sili U, et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med. 2006;12(10):1160-1166.. (Pubitemid 44527351)